2/After 50 years of adjuvant trials on RCC (3 slides); #KEYNOTE564 demonstrates overall survival (OS) benefit!

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

🚨📢Just published! The first trial that showed an overall survival benefit in patients with renal cell carcinoma in the adjuvant setting (KEYNOTE-564) out in NEJM 🚨 ⭐️💫

Toni Choueiri, MD Dana-Farber Tom Powles OncoAlert Dana-Farber_GU

nejm.org/doi/full/10.10…

What are the challenges with diagnosing #RenalMedullaryCarcinoma ? Dr. Nizar Tannir from
MD Anderson Cancer Center via Patient Empowerment Network explains: bit.ly/3U4gjwF #RMC ,   #kidneycancer
R.M.C. Inc KidneyCAN Chris Johnson Foundation Inc. RMC Alliance @KidneyCanc KCCure

Registration is open for the KidneyCAN town hall on clinical trials: kidneycan.org/real-talk-on-k… KidneyCAN

The OncoAlert 🚨ROUND UP
Covering April 5th-12th, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Discussing:
✅ U.S. FDA 🇺🇸approval trastuzumab dx
fda.gov/drugs/resource…

✅ Durvalumab in🫁 Small Cell #LungCancer
astrazeneca.com/media-centre/p…

✅ Alina out

Guided by a rich portfolio of ongoing efforts, National Cancer Institute is seizing opportunities to fund new health disparities studies, diversify our pipeline of talent, and ensure that clinical studies include and benefit minority populations. #HealthDisparities spr.ly/6019wsA5v

NCI Director’s Address and Fireside Chat — Dr. Kimryn Rathmell W. Kimryn Rathmell spoke Monday at #AACR24 about the importance of innovative collaborations in the fight to end cancer. Read a recap in AACR Annual Meeting News: bit.ly/3JeyISE

Congrats KidneyCAN thanks for your advocacy and organization! Through this networking we strive to improve research leading to increased cure for #kidneycancer

Last call! Applications for the AACR-KidneyCAN grants are due TODAY by 1:00 pm ET!

bit.ly/AACR-KidneyCAN…

Get those proposals in! Let's #AccelerateCures for #KidneyCancer !

Any patient w #kidneycancer is welcome to attend our KidneyCancerProgram education symposium in Dallas Sat 4/27! Come learn from my colleagues James Brugarolas Hans Hammers Payal Kapur & many more #kidneycancer experts.
Register here: bit.ly/3VyG4rt
Kidney Cancer KCCure KidneyCAN

Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study:
⭕️Final CLEAR trial results: Lenvatinib+pembrolizumab reduces mortality risk by 21% vs sunitinib in advanced RCC.
⭕️While median OS is similar, the combo’s lower HR & tight 95% CI underscore its robust…

According to the NIH, cancer prevention isn’t just about avoiding the disease—it’s about taking steps to reduce risk. With over 2 million new cancer diagnoses expected in 2024, prevention is key. OVAC advocates for increased funding for early detection.

An update: this event is now open to ALL kidney cancer patients, regardless of where they're receiving treatment- we want these resources to be available to any patient experiencing kidney cancer diagnosis, treatment, or survivorship.
RSVP here: bit.ly/3VyG4rt